Pre Seed · Biotech · Copenhagen, Denmark · Founded 2019 · 1–8 employees
BOOST Pharma is developing a first-in-class stem cell therapy called BT-101 for treating Osteogenesis Imperfecta (OI), a rare genetic bone disorder affecting children. Their innovative mesenchymal stem cell therapy has shown over 75% reduction in fracture rates in Phase I/II trials. The company has received FDA Rare Pediatric Disease designation and Orphan Drug status in both US and Europe. Based on 20+ years of research from Karolinska Institute, they have successfully treated children since 2002 and secured funding from multiple investors including Sound Bioventures with €3.1 million in late 2025.
No open roles listed right now.